Business - Webflow HTML website template

ProBioPharm

Providing strategy, business development, and commercialization expertise to biotech, pharmaceutical, and vaccine companies.

Our Specialty is

Getting deals done to bring new products and technologies to market.

Jim Self, President

An accomplished executive, with over 30 years of pharmaceutical and business development experience, Jim has worked globally with scientists, entrepreneurs, and business leaders in biotech, pharmaceutical, and healthcare. He works with companies large and small, across cultures, to craft business deals and marketing strategies that deliver value.

Prior to founding ProBioPharm, Jim Self was the Global Leader of Business Development for Merck’s Vaccine Division. He spent over 15 years in various Merck business development groups completing business transactions around the world.

Jim earned an MBA from Wharton Business School and an undergraduate degree in Industrial Engineering from NC State University.

Services

What we do.

ProBioPharm specializes in working directly with the CEO and executive team of biotech, pharmaceutical, and healthcare companies to identify, source and execute on business development priorities.

Our speciality is developing and executing partnering strategies, including but not limited to distributorships, in-licensing, out-licensing, R&D Collaborations, Joint Ventures, Divestitures, Acquisitions, and other strategic partnerships.

Our Work

Testimonials

Joan Lau, PhD

CEO, Spirovant Sciences, Founding Partner, Militia Hill Ventures

"Passionate, smart and well-connected. Jim is a terrific partner for thinking through corporate and business strategy. He never loses sight of the business objective and excels at crafting deals that help companies succeed. Whether it's fundraising, a research collaboration, licensing, or company sale, Jim is obsessed with getting deals done. I strongly recommend Jim and ProBioPharm.”

Margie McGlynn

President, Merck Vaccines (Ret.) Board Member, Abcombi Biosciences

“I worked with Jim at Merck Vaccines and more recently at Abcombi, where he has fine tuned the company’s strategy to secure financial resources and driven the process to pursue strategic partnerships. He is a very capable and effective executive who knows how to create financial and strategic value for both parties in a transaction.”

Michael Bolick

CEO, Selah Technologies

“Jim Self is an outstanding strategic thinker. His keen intellect, impressive work experience and integrity combine to enable sound judgment and wise counsel. Jim's generous service on Selah Technologies' Board was a blessing which helped us to successfully transition from an exciting startup commercializing nanotechnology to the US Headquarters for Lab21.”